Logo

Atea Reports Results of AT-527 in P-II MOONSONG Trial for the Treatment of COVID-19

Share this
Atea Reports Results of AT-527 in P-II MOONSONG Trial for the Treatment of COVID-19

Atea Reports Results of AT-527 in P-II MOONSONG Trial for the Treatment of COVID-19

Shots:

  • The P-II MOONSONG trial evaluates the antiviral activity- safety & PK of AT-527 (550/1100 mg- bid) vs PBO in adult patients with COVID-19. The therapy is jointly developed in collaboration with Roche
  • The trial did not meet its 1EPs of reduction from baseline in SARS-CoV-2 virus in an overall study population- two-thirds of patients had low-risk with mild symptoms. In high-risk patients- a reduction of viral load of ~0.5 log10 @ 7 Day was observed at both doses- was generally safe & well tolerated
  • AT-527 is non-mutagenic & has no effects on fertility & reproduction. The therapy is being evaluated across multiple P-II & III clinical trials & P-III MORNINGSKY data is expected in H2’22

Click here to­ read the full press release/ article | Ref: Atea Pharma | Image: Atea Pharma


Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

We Have a Viewership of 1,00,000 + Views

Join the PharmaShot Family